On December 4, 2023 Clinical stage drug developer Syntara reported that the Australian Securities and Investment Commission has issued a Certificate of Registration on Change of Name from Pharmaxis Ltd to Syntara Limited (Press release, Syntara, DEC 4, 2023, View Source [SID1234639973]). This follows approval at last week’s 2023 annual general meeting where the resolution to change the name was supported by 98% of voting shareholders.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The change in the Company’s ASX code from PXS to SNT is currently being processed by the ASX.